phosphorylcholine has been researched along with Arteriosclerosis in 14 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized and double blind experiment has been made over 50 patients and 25 checks, by giving a dosage of 3 Fosfolip (calcium salt of phosphorylcholine chlorid with pantethine) capsules a day." | 2.65 | [Clinical study of the lipotropic activity of the preparation Fosfolip]. ( Chiti, D; Ligas, B; Proietti, C, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Purkall, D | 1 |
| Tew, JG | 1 |
| Schenkein, HA | 1 |
| Shaw, PX | 2 |
| Goodyear, CS | 1 |
| Chang, MK | 1 |
| Witztum, JL | 2 |
| Silverman, GJ | 2 |
| Black, S | 1 |
| Kushner, I | 1 |
| Samols, D | 1 |
| Ligas, B | 2 |
| Proietti, C | 3 |
| Chiti, D | 3 |
| Bagliani, A | 1 |
| Argenteri, A | 1 |
| La Rosa, A | 1 |
| Kearney, JF | 1 |
| Luo, L | 1 |
| Dwyer, D | 1 |
| Chang, M | 1 |
| Horkko, S | 1 |
| Palinski, W | 1 |
| Stall, A | 1 |
| Nofer, JR | 1 |
| Levkau, B | 1 |
| Wolinska, I | 1 |
| Junker, R | 1 |
| Fobker, M | 1 |
| von Eckardstein, A | 1 |
| Seedorf, U | 1 |
| Assmann, G | 1 |
| Carson, MJ | 1 |
| Lo, D | 1 |
| Kabarowski, JH | 1 |
| Zhu, K | 1 |
| Le, LQ | 1 |
| Witte, ON | 1 |
| Xu, Y | 1 |
| Mookerjea, S | 1 |
| Pepys, MB | 1 |
| Rowe, IF | 1 |
| Baltz, ML | 1 |
| Imperiale, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
4 reviews available for phosphorylcholine and Arteriosclerosis
| Article | Year |
|---|---|
C-reactive Protein.
Topics: Animals; Arteriosclerosis; C-Reactive Protein; Complement C1q; Gene Expression Regulation; Humans; I | 2004 |
Immune recognition of OxLDL in atherosclerosis.
Topics: Animals; Antibody Formation; Arteriosclerosis; Autoantibodies; B-Lymphocytes; Humans; Lipoproteins, | 2000 |
Neo-self antigens and the expansion of B-1 cells: lessons from atherosclerosis-prone mice.
Topics: Animals; Antibodies, Antiphospholipid; Apolipoproteins E; Arteriosclerosis; Autoantibodies; Autoanti | 2000 |
C-reactive protein: binding to lipids and lipoproteins.
Topics: Animals; Arteriosclerosis; Binding Sites; Blood Platelets; C-Reactive Protein; Calcium; Cell Membran | 1985 |
2 trials available for phosphorylcholine and Arteriosclerosis
| Article | Year |
|---|---|
[Clinical study of the lipotropic activity of the preparation Fosfolip].
Topics: Adult; Aged; Arteriosclerosis; Choline; Clinical Trials as Topic; Double-Blind Method; Drug Combinat | 1983 |
[Double-blind trial on the trophic and anti-atherosclerotic preventive efficacy of a phosphorylcholine-pantetheine combination].
Topics: Aged; Arteriosclerosis; Choline; Double-Blind Method; Drug Combinations; Drug Evaluation; Female; Hu | 1985 |
8 other studies available for phosphorylcholine and Arteriosclerosis
| Article | Year |
|---|---|
Opsonization of Actinobacillus actinomycetemcomitans by immunoglobulin G antibody reactive with phosphorylcholine.
Topics: Aggregatibacter actinomycetemcomitans; Antibodies, Bacterial; Arteriosclerosis; Humans; Immunoglobul | 2002 |
The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells.
Topics: Animals; Antibodies, Antiphospholipid; Apoptosis; Arteriosclerosis; Autoantigens; Binding Sites, Ant | 2003 |
[Clinical study of the combination of calcium phosphorylcholine and pantetheine].
Topics: Adult; Aged; Arteriosclerosis; Choline; Drug Therapy, Combination; Female; Humans; Lipidoses; Male; | 1983 |
[Treatment of hyperdyslipidemia in chronic atherosclerotic peripheral obliterating arteriopathies of the lower limbs].
Topics: Adult; Aged; Arterial Occlusive Diseases; Arteriosclerosis; Cholesterol; Choline; Female; Humans; Hy | 1982 |
Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids.
Topics: Apoptosis; Arteriosclerosis; Cell Survival; Cells, Cultured; Endothelium, Vascular; Humans; Lipoprot | 2001 |
Immunology. The push-me pull-you of T cell activation.
Topics: Animals; Antigen Presentation; Antigens; Arteriosclerosis; B-Lymphocytes; Cell Cycle Proteins; Human | 2001 |
Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A.
Topics: Animals; Arteriosclerosis; Calcium; Cell Cycle Proteins; Cell Line; Chemotaxis, Leukocyte; Humans; J | 2001 |
Mechanism of heparin and serum lipoprotein interaction: effects of calcium, phosphorylcholine, and a serum fraction.
Topics: Animals; Arteriosclerosis; Blood Proteins; Calcium; Chemical Phenomena; Chemical Precipitation; Chem | 1978 |